Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Preferred Stock Liabilities: 2015-2023

  • Cartesian Therapeutics' Preferred Stock Liabilities was N/A to $296.9 million in Q4 2023 from the same period last year, while for Dec 2023 it was $296.9 million, marking a year-over-year change of. This contributed to the annual value of $296.9 million for FY2023, which is N/A change from last year.
  • Cartesian Therapeutics' Preferred Stock Liabilities amounted to $296.9 million in Q4 2023, which was up 5,837.02% from $5.0 million recorded in Q2 2016.
  • Cartesian Therapeutics' 5-year Preferred Stock Liabilities high stood at $296.9 million for Q4 2023, and its period low was $296.9 million during Q4 2023.
  • In the last 1 years, Cartesian Therapeutics' Preferred Stock Liabilities had a median value of $296.9 million in 2023 and averaged $296.9 million.